Marie Kondo's famous book on cleaning out your closet contains some helpful hints that are easily applied to your portfolio. Use this mid-winter bounce to clean out your stocks. Read More
The following search results are from Investing Daily's public research only. Please Log In to search your premium services.
Results
An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More
Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More
Electric vehicle maker Tesla announced earnings last week. The earnings call implies that the company faces a challenging road ahead. Read More
This maker of cannabis-infused medical treatments is a pre-clinical stage biotech with a small market cap. As such, it's a dangerous stock. But do the opportunities outweigh the risks? Read More
An examination of a marijuana "infrastructure play," its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More
The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More
This mid-cap biotech is developing novel drugs for diseases that resist conventional therapies. Is Arena a future "rocket stock" or will it blow up on the launch pad? Read More
As these three blue chip stocks prove, sentiment moves the market in the short-term but fundamentals win out over the long-term. Read More
This cannabis biotech is a micro-cap garnering Wall Street's attention. As investors flock to pot investments, is United Cannabis an appealing play or risky penny stock? Read More
Stock Talk Results
No Comments Found